Specialist Physician Engagement
Novartis deploys highly trained medical science liaisons and specialty sales forces targeting oncologists, cardiologists, rheumatologists, and neurologists — the prescribers who determine formulary adoption for high-value specialty medicines. This physician-centric approach is reinforced by robust clinical data packages and medical education programs.
In key markets including the United States, Novartis has pioneered outcome-based pricing agreements with payers — most notably for Kymriah, where the company offered to charge only if patients responded at 30 days. This approach aligns commercial incentives with clinical outcomes and differentiates Novartis in payer negotiations.